Large molecule bioanalytical testing services provider BioAgilytix has snapped up a rival firm in Cambridge Biomedical.
The Boston-based CRO also specializes in large molecule bioanalysis; but, while adding to its own service, the acquisition also helps BioAgilytix boost its global footprint into the biotech hub that is Boston while joining Cambridge Biomedical’s CLIA-certified, CAP-accredited and GLP-compliant facility with its GxP laboratories in Durham, North Carolina, and Hamburg, Germany.
“It also grows BioAgilytix’s premier team to more than 400 employees worldwide, bringing on board Cambridge Biomedical’s seasoned bioanalytical scientists to complement and further enhance BioAgilytix’s world-class expertise in biomarkers, immunogenicity, cell-based assays, and pharmacokinetics to support all phases of biologics development,” the company said.
Financial details of the deal were not disclosed.
“We’re proud to have Cambridge Biomedical join BioAgilytix in our collective mission to serve customers’ evolving and expanding bioanalytical needs,” said Jim Datin, president and CEO of BioAgilytix.
“Our companies have many synergies, both exclusively focused in large molecules and today supporting development of some of the most innovative and complex biologics, including cell and gene therapeutics. Together we will be able to offer the same premier scientific solutions and quality results, but on a larger scale.”
“As we were considering the best way to enable Cambridge Biomedical to continue on its strong growth trajectory, it became clear that we wanted a partner, one as committed to upholding our high scientific standards and ‘people first’ values,” added Barbara Osband, founder and chief at Cambridge Biomedical.
“Having personally spent more than 18 years building our business and creating a culture that recognizes being in the health care industry mandates a special level of competence, caring, and integrity, I was thrilled to merge with BioAgilytix whose value systems mirror our own. I couldn’t be more confident placing Cambridge Biomedical in the capable hands of BioAgilytix’s leadership team.”